Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  DRG Market Assessment Reports

Prostate Cancer | Treatment Sequencing | US | 2019

Login to access report north_east
Contact sales account_box

KEY BENEFITS AND USES

  • Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.
  • Drill down into physicians’ treatment sequences and understand who to position against or how to defend share.
  • Identify untapped treatment scenarios and key competitors to aid trial design.
  • Evaluate unique disease-specific treatment patterns and dynamics to plan and manage sales and marketing resources and execute commercialization messages.
  • Discover untapped populations to expand product share and drive strategic decisions.

QUESTIONS ANSWERED
• Where is my product positioned vs. competitors in the treatment journey?
• What are physicians’ most frequent treatment sequences—who is
benefiting and how can I defend my assets share and position?
• What are the market-relevant treatment scenarios according to oncology
experts?
• Where are the untapped business opportunities that I can capitalize
upon?
• How can I optimize trial design and ensure a competitive edge for my
pipeline asset?

GEOGRAPHIES
United States
PRIMARY MARKET RESEARCH
Survey of ~100 U.S. physicians
2019 COVERAGE
Colorectal Cancer (US)
Multiple Myeloma (US)
Non-Hodgkin’s Lymphoma and
Chronic Lymphocytic Leukemia
(US)
Non-Small-Cell Lung Cancer (US)
Ovarian Cancer (US)
Prostate Cancer (US)
Renal Cell Carcinoma (US)

KEY FEATURES

  • Market-relevant treatment scenarios and subpopulations from oncology experts
  • Drug share and treatment rates mapped to treatment journey using physician survey data
  • Physicians’ most frequently selected treatment sequences
  • Access to expert oncology analysts for bespoke support

PRODUCT DESCRIPTION
Treatment Sequencing provides disease-specific, sequential treatment
patterns in market-relevant treatment scenarios and drug share mapped to
treatment journey. The quantitative sequencing analysis illuminates drug
positioning through primary market research-based insights from physicians
and DRG oncology experts’ assumptions.

Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Psoriasis – Unmet Need – Unmet Need – Moderate to Severe Psoriasis (US/EU)
Topical therapies are the backbone of psoriasis management; however, they are often inadequate for patients with moderate to severe disease, who typically require systemic treatment. While…
north_east
Report
Non-Small-Cell Lung Cancer – Unmet Need – Unmet Need – Metastatic NSCLC without driver mutations (US EU)
First-line treatment for non-small-cell lung cancer (NSCLC) patients without driver mutations typically includes an immune checkpoint inhibitor, with or without platinum-based chemotherapy,…
north_east
Report
Eosinophilic Esophagitis – Unmet Need – Unmet Need – Eosinophilic Esophagitis (US/EU)
Standard treatments for eosinophilic esophagitis (EoE) typically include proton pump inhibitors (PPIs) and swallowed topical steroids. Although these therapies can alleviate EoE symptoms, their…
north_east
Report
Breast Cancer – Geographic Focus: China – China In-Depth – Breast Cancer
China’s breast cancer market continues to evolve rapidly, driven by rising incidence and expanding systemic treatment options. Several new and emerging therapies are expected to gain approval for…
north_east
Report
Chronic Obstructive Pulmonary Disease – Unmet Need – Unmet Need – Severe to Very Severe Chronic Obstructive Pulmonary Disease (US EU)
The severe to very severe chronic COPD market is crowded, with numerous LAMA, LABA/ICS, LABA/LAMA, and triple LABA/LAMA/ICS inhalers competing for use. Although dual and triple longacting…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east